How to Source Fenofibrate Caplets and Capsules for Pharmaceutical Formulation

Fenofibrate Caplets and Capsules (Caplets and Capsules, 67 mg, 135 mg, 160 mg, and 145 mg) is classified under Heart Disorder. It is therapeutically aligned with reference brands such as Tricor(US), Fenogal, Lipanor(EU). This guide highlights key sourcing factors buyers should consider when procuring high-quality Fenofibrate Caplets and Capsules for formulation, R&D, or bulk manufacturing.

1. Regulatory Compliance & Documentation

Ensure suppliers provide:

• ✔ Valid DMF (Drug Master File)
• ✔ COA (Certificate of Analysis) for each batch
• ✔ GMP, ISO, or ICH Q7 compliance certificates

2. Purity, Grade & Specification Matching

Fenofibrate Caplets and Capsules must meet exact grade and purity for your dosage form:

• ✔ USP / EP / JP grade verification
• ✔ Particle size distribution check
• ✔ Residual solvent and heavy metal limits

3. Supplier Reliability & Audit History

• ✔ Positive past audit reports
• ✔ Pharma client references
• ✔ Years of proven API manufacturing experience

4. Commercial Terms: Pricing, MOQ & Flexibility

• ✔ Transparent pricing
• ✔ Pilot batch MOQ flexibility
• ✔ Volume-based discounts

5. Lead Time, Inventory & Logistics

Typical lead time for Fenofibrate Caplets and Capsules is 4–6 weeks.

• ✔ Emergency dispatch options
• ✔ Regional warehousing
• ✔ Special storage if needed

6. Formulation Support

• ✔ Technical datasheets
• ✔ Sample availability
• ✔ Stability study support

Conclusion

Sourcing Fenofibrate Caplets and Capsules is more than procurement—it’s a strategic partnership. With its caplets and capsules form and 67 mg, 135 mg, 160 mg, and 145 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.

Frequently Asked Questions For Sourcing of Fenofibrate Caplets and Capsules